Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SJP 002C

Next Previous
Drug Profile

SJP 002C

Alternative Names: SARS CoV2 therapeutic - Sen-Jam Pharmaceutical; SJP-002C

Latest Information Update: 22 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sen Jam Pharmaceutical
  • Developer Duke-NUS Graduate Medical School Singapore; Sen Jam Pharmaceutical
  • Class Antihistamines; Antivirals; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II COVID 2019 infections

Most Recent Events

  • 12 Aug 2025 Sen-Jam Pharmaceutical finalizes the US FDA ready CMC package and confirmed six-month stability data, enabling the immediate launch of a phase IIb clinical trial in COVID-19 infections
  • 28 Sep 2024 No recent reports of development identified for clinical-Phase-Unknown development in COVID-2019-infections in USA (PO)
  • 01 Jul 2024 Sen Jam Pharmaceutical plans to seek US FDA approval to commence a phase III trial in COVID-2019 infections

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top